What dosing adjustments are recommended for dalbavancin in patients with reduced creatinine clearance?

Dalbavancin Dosing in Renal Impairment

For adult patients with creatinine clearance <30 mL/min who are not on regularly scheduled hemodialysis, reduce the dalbavancin dose to 1,125 mg total—either as a single dose or as 750 mg followed by 375 mg one week later. 1

Dosing Algorithm by Renal Function

Adults with Normal to Moderate Renal Impairment (CrCl ≥30 mL/min)

• Standard dosing: 1,500 mg total dose
  • Either single 1,500 mg dose, OR
  • 1,000 mg on Day 1, then 500 mg on Day 8
• No adjustment needed 1

Adults with Severe Renal Impairment (CrCl <30 mL/min, NOT on dialysis)

• Reduced dosing: 1,125 mg total dose
  • Either single 1,125 mg dose, OR
  • 750 mg on Day 1, then 375 mg on Day 8
• Rationale: Dalbavancin AUC increases approximately 100% in severe renal impairment 2

Adults on Regularly Scheduled Hemodialysis

• Standard dosing: 1,500 mg (no adjustment)
• Timing: Can be administered without regard to hemodialysis schedule
• Key point: Hemodialysis does not significantly remove dalbavancin 1, 2

Pediatric Patients (Birth to <18 years) with CrCl ≥30 mL/min/1.73m²

• Birth to <6 years: 22.5 mg/kg (maximum 1,500 mg) as single dose
• 6 to <18 years: 18 mg/kg (maximum 1,500 mg) as single dose
• Important caveat: Insufficient data exist for pediatric dose adjustment when CrCl <30 mL/min/1.73m² 1

Pharmacokinetic Basis

Dalbavancin undergoes approximately 45% renal elimination with the remainder via non-renal clearance 3. The drug exhibits:

• Clearance: 0.066 L/h in typical patients
• Half-life: Approximately 300 hours (>1 week), even longer in tissues 3, 4
• Protein binding: 93%, which influences free drug exposure 3

In moderate renal impairment (CrCl 30-79 mL/min), mean AUC increases approximately 50%, while severe impairment (CrCl <30 mL/min) doubles the AUC 2. However, the high protein binding means that free drug concentrations—the pharmacologically active fraction—increase proportionally less than total drug.

Critical Considerations

Obesity and preserved kidney function: Recent evidence suggests standard dosing may provide inadequate exposure in patients with obesity (BMI >30) or eGFR ≥120 mL/min, particularly for prolonged therapy beyond the approved 2-week course 5. In these populations, standard regimens achieved only 50-60% probability of target attainment at 4 weeks. However, these data apply to off-label prolonged therapy, not the FDA-approved acute bacterial skin and skin structure infection indication.

Hepatic impairment: No dose adjustment is required for any degree of hepatic dysfunction. AUC values were actually 27-36% lower in moderate-to-severe hepatic impairment compared to controls 2.

Dialysis considerations: For patients on peritoneal dialysis, insufficient data exist to make firm recommendations—use with caution 1.

Common Pitfalls

1. Do not reduce dose for mild-moderate renal impairment (CrCl 30-79 mL/min)—this is unnecessary and may lead to subtherapeutic exposure
2. Do not give supplemental doses after hemodialysis—the drug is not significantly removed by dialysis
3. Do not adjust dosing based on age alone in elderly patients, though recognize that renal function naturally declines with age and should be assessed 2
4. For pediatric patients with renal impairment: No validated dosing exists for CrCl <30 mL/min/1.73m²—consider alternative therapy or expert consultation

The dose reduction in severe renal impairment (to 75% of standard dose) balances the need to avoid toxicity from drug accumulation while maintaining adequate exposure, given dalbavancin's concentration-dependent killing and the pharmacodynamic target of fAUC/MIC ≥27.1 for efficacy 3, 6.